These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 16262557)
1. The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Uzan A Expert Opin Emerg Drugs; 2005 Nov; 10(4):687-8. PubMed ID: 16262557 [TBL] [Abstract][Full Text] [Related]
2. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859 [TBL] [Abstract][Full Text] [Related]
3. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF; Hsiao FY; Wen YW; Tsai YW Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966 [TBL] [Abstract][Full Text] [Related]
7. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Chan FK; Abraham NS; Scheiman JM; Laine L; Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Borer JS; Simon LS Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077 [TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. Hennekens CH; Borzak S J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589 [TBL] [Abstract][Full Text] [Related]
10. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. Scheiman JM Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260 [TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs]. van den Bemt BJ; Benraad HB; Rasker JJ Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. Dajani EZ; Islam K J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Joshi GP; Gertler R; Fricker R Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885 [TBL] [Abstract][Full Text] [Related]
14. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336 [TBL] [Abstract][Full Text] [Related]
15. COX-2 inhibitors: pharmacological data and adverse effects. Mattia C; Coluzzi F Minerva Anestesiol; 2005; 71(7-8):461-70. PubMed ID: 16012420 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817 [TBL] [Abstract][Full Text] [Related]
17. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]. Nurmohamed MT Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165 [No Abstract] [Full Text] [Related]
18. Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Aneja A; Farkouh ME Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):53-66. PubMed ID: 19124408 [TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Scarpignato C; Hunt RH Gastroenterol Clin North Am; 2010 Sep; 39(3):433-64. PubMed ID: 20951911 [TBL] [Abstract][Full Text] [Related]
20. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Targownik LE; Metge CJ; Leung S; Chateau DG Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]